Skip to content


BMC Cancer

Open Access

Correction to: Metabolomic profiling identifies distinct phenotypes for ASS1 positive and negative GBM

BMC Cancer201818:268

Received: 13 February 2018

Accepted: 13 February 2018

Published: 8 March 2018

The original article was published in BMC Cancer 2018 18:167


In the original publication of this article [1], published on 8 February 2018, it was noticed that the acknowledgement of the source of the drug ADI-PEG20 was missing. In this Correction, the source of drug ADI-PEG20 is shown (and marked bold). This addition is made in the Methods section, under the heading ADI-PEG20 treatment.

ADI-PEG20 treatment.

SNB19 and U87 cells, cultured in DMEM + 10% FBS and normal human astrocytes, cultured in speciality media provided by lonza were seeded in replicates (n = 12) at 8 × 104 cells per well in 6-well dishes (Corning, NY, USA). 24 h post seeding, cells were washed with phosphate buffered saline (PBS) and cultured in the presence or absence of ADI-PEG20 (kindly provided by Polaris Pharmaceuticals Inc, San Diego, CA) (1 μg/ml) in media containing, 1 mM citrulline and 10% fetal FBS. ADI- PEG20 was added at the start of the experiment and no fresh media was added to any of the experimental plates before harvesting. ADI-PEG20 treated and untreated media (n = 3) was included for normalization purposes. 48 h after ADI-PEG20 treatment replicate samples for each condition (n = 3) were harvested, collecting both spent media and cells for GC-TOFMS metabolomic ana- lysis. Additional replicates (n = 3) of each condition were collected for total cell count determination.



Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (, which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

Department of Chemistry, Umeå University, Umeå, Sweden
John Fulcher Neuro-Oncology Laboratory, Imperial College London, London, UK
St Luke’s Cancer Centre, Royal Surrey County Hospital, Guildford, UK


  1. Mörén L, et al. Metabolomic profiling identifies distinct phenotypes for ASS1 positive and negative GBM. BMC Cancer. 2018;18:167. ArticlePubMedPubMed CentralGoogle Scholar


© The Author(s). 2018